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ABSTRACT

Objectives Patients with type 2 diabetes have a higher
risk of colorectal cancer (CRC), but whether Chinese herbal
medicines (CHMs) can reduce this risk is unknown. This
study investigated the effect that CHMs have on CRC risk
in patients with type 2 diabetes.
Research design and methods This cohort study
used the Taiwanese National Health Insurance Research
Database to identify 54 744 patients, newly diagnosed with
type 2 diabetes, aged 20–70 years, who were receiving
treatment between 1998 and 2007. From this sample,
we randomly selected 14 940 CHMs users and 14 940
non-CHMs users, using propensity scores matching. All
were followed through 2012 to record CRC incidence. Cox
proportional hazards regression was used to compute the
hazard ratio (HR) of CRC by CHMs use.
Results During follow-up, 235 CHMs users and 375 non-
CHMs users developed CRC, incidence rates of 1.73%
and 2.47% per 1000 person-years, respectively. CHM
users had a significantly reduced risk of CRC compared
with non-CHM users (adjusted HR=0.71; 95% CI 0.60 to
0.84). The greatest effect was in those receiving CHMs for
more than 1 year. Huang-Qin, Xue-Fu-Zhu-Yu-Tang, Shu-
Jing-Huo-Xue-T ang, Liu-Wei-Di-Huang-Wan, Ji-Sheng-
Shen-Qi-Wan, Gan-Lu-Y in, Shao-Yao-Gan-Cao-Tang and
Ban-Xia-Xie-Xin-Tang were significantly associated with
lower risk of CRC.
Conclusion Integrating CHMs into the clinical
management of patients with type 2 diabetes may be
beneficial in reducing the risk of CRC.

Introduction
Diabetes mellitus has become an increasingly
prevalent chronic condition that affects more
than 400 million people worldwide.1 Over the
past 50 years, numerous studies have linked
diabetes, in particular type 2 diabetes, to a
higher risk of cancer. It is noteworthy that
the risk of colorectal cancer (CRC), the third
most common cancer around the world,
is estimated to be 27% higher in patients
with type 2 diabetes than in non-
diabetic
control patients.2 According to the WHO,
approximately 1.8 million patients are newly

Significance of this study
What is already known about this subject?
►► Despite recent improvements in diabetes treatment,

those with type 2 diabetes are still found to have
higher risk of cancer, especially colorectal cancer
(CRC).
►► Recently, Chinese herbal medicines have become
increasingly popular as an adjunctive treatment for
patients with chronic diseases; nevertheless, association of Chinese herbal medicines and the risk
of CRC among patients with type 2 diabetes is still
unknown.

What are the new findings?
►► This retrospective 15-
year cohort study clarified

the therapeutic effect of Chinese herbal medicines
on the subsequent risk of CRC among patients with
type 2 diabetes.
►► The most prominent effect was observed among
those receiving Chinese herbal medicines for more
than 1 year.

How might these results change the focus of
research or clinical practice?
►► The reported findings serve an important role for

healthcare providers in helping to guide more effective treatment strategies to improve clinical outcomes for patients with type 2 diabetes.
►► The corresponding findings could serve as a reference for further pharmacological studies and clinical
trials.

diagnosed with CRC, and over 800 000 die
annually from this cancer.3
In Taiwan, CRC is commonly diagnosed and
is the third leading cause of cancer-related
death. Massive developments in specialized
diagnostic and therapeutic methods have
improved the survival of patients with type
2 diabetes. Some studies have indicated that
the long-term use of insulin or sulfonylureas
may predispose patients with type 2 diabetes
to develop CRC.4 5 In view of this concern, it is
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Decreased risk of colorectal cancer
among patients with type 2 diabetes
receiving Chinese herbal medicine: a
population-based cohort study

Epidemiology/Health Services Research

Research design and methods
Data source
For this study, we used a publicly released cohort dataset,
the Longitudinal Health Insurance Database (LHID),
comprised of approximately 1 000 000 randomly sampled
people and obtained all records from 1996 to 2012. The
database has been confirmed by the National Health
Research Institute to be representative of the Taiwanese
population and its data have been used in many previously
published scientific papers.14 The encrypted information
protects patient privacy and allows linkage of all claims
for the same patient within the database. This database
contains all National Health Insurance (NHI) enrolment
files, claims data and the registry for prescription drugs
and provides comprehensive information on all individuals covered by the insurance program. This study was
conducted in accordance with the Helsinki Declaration
and was evaluated and approved by the local Institutional
Review Board and ethics committee of Buddhist Dalin
Tzu Chi Hospital, Taiwan (No. B10004021-2).
Study population
Patients, 20–70 years of age, newly diagnosed with type
2 diabetes between 1998 and 2007 were identified
(figure 1). To be included, patients with type 2 diabetes
had to have at least three ambulatory or inpatient claims
with the International Classification of Disease, 9th
edition, Clinical Modification (ICD-9-
CM) diagnosis
2

Figure 1 Flowchart of study and follow-up of study
participants. CHMs, Chinese herbal medicines; NHI, National
Health Insurance.

CM
code 250 and excluding type 1 diabetes (ICD-9-
code 2501). A total of 208 cases with type 2 diabetes
were then excluded because of prior diagnosis of CRC
(ICD-9-
CM codes colon cancer: 153x, rectal cancer:
154x). This exclusion was indicated by linking type 2
diabetes subjects to the catastrophic illness registry. In
Taiwan, insured residents with major diseases (eg, cancer,
autoimmune diseases, chronic renal failure) can apply
for a catastrophic illness certificate that grants exemption from copayment. Those with a follow-up period <3
months were also excluded (n=38). Additionally, given
the protective effect of metformin in decreasing the
onset of cancer,15 those patients who received in the past
metformin with an average dose of more than 250 mg per
day were also excluded (n=14 457). Overall, we identified
40 041 subjects with new-onset type 2 diabetes.
In Taiwan, only certified Chinese medicine physicians
are entitled to prescribe CHMs. We used the frequency
of visits to a Chinese medicine physician to verify the
CHMs exposure of each subject with type 2 diabetes.
Those receiving CHMs after their initial diagnosis of
type 2 diabetes for more than 30 days were identified
as CHMs users, whereas those treated for 30 days or less
were considered non-CHMs users.8 Based on this rule,
15 150 cases were designated as CHMs users. A comparison cohort was randomly selected from the remaining
insured type 2 diabetes cases without CHMs use. For each
type 2 diabetes case who received CHMs treatment, one
control case without CHMs treatment was selected, using
a 1:1 match based on a propensity score. Propensity scores
representing the likelihood of receiving CHMs were
calculated using logistic regression analysis, conditional
on the baseline covariates listed in table 1. Accordingly,
an equal number of patients in the CHMs and non-CHMs
cohorts were analyzed in this study. The index date for
BMJ Open Diab Res Care 2020;8:e000732. doi:10.1136/bmjdrc-2019-000732
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of therapeutic interest to explore alternative treatments
that may lessen this risk.
With few side effects, Chinese herbal medicines
(CHMs) had been used for patients with chronic illnesses
such as dementia,6 hepatocellular carcinoma7 and
vertigo.8 Several randomized clinical trials have further
suggested that CHMs could delay the progression of
distal symmetric polyneuropathy9–11 and nephropathy.12
More specifically, research findings have suggested that
CHMs protect against CRC risk by improving the antitumor activity of the chemotherapy drug 5-fluorouracil
against the HT-29 colon cancer cell,13 implying that CHMs
should not be neglected in the treatment of patients with
type 2 diabetes.
Given the possible beneficial effect of CHMs on
subsequent CRC risk, and the limited information on
whether CHMs could modify the relationship between
type 2 diabetes and CRC risk, findings from a long-term
population-based cohort study might be useful in allocating medical resources and in instituting fact-
based
policymaking for the treatment of CRC among patients
with type 2 diabetes. Nevertheless, to date, no clinical
observations or empirical data have documented this
potential benefit for patients with type 2 diabetes. Therefore, in this study, we analyzed a nationwide population-
based database to compare the risk of CRC among
patients with type 2 diabetes who either did or did not
receive CHMs.

Epidemiology/Health Services Research

Variables

CHMs non-
users

CHMs users

n=14 940 (%)

n=14 940 (%)

Age, (years)

0.75

 ≤50

5259 (35.2)

5274 (35.3)

 >50

9681 (64.8)

9666 (64.7)

 Mean (SD)

53.93±10.32

53.86±10.42

Gender

0.74
0.50

 Female

8396 (56.2)

8337 (55.8)

 Male

6544 (43.8)

6603 (44.2)

Monthly income

0.51

 Low

5692 (38.1)

5677 (38.0)

 Median

8411 (56.3)

8381 (56.1)

837 (5.6)

882 (5.8)

 High

P
value

Residential area

0.28

 Urban

8725 (58.4)

8650 (57.9)

 Suburban

2256 (15.1)

2346 (15.7)

 Rural

3959 (26.5)

3944 (26.5)

 Hypertension

6917 (46.3)

6872 (46.0)

0.49

 Stroke

1121 (7.5)

1150 (7.7)

0.53

 Heart disease

2928 (19.6)

2928 (19.6)

0.99

 Chronic kidney
disease

194 (1.3)

194 (1.3)

0.67

 Depression

493 (3.3)

538 (3.6)

0.16

 Rheumatologic
disorders

105 (0.7)

105 (0.7)

0.77

Comorbidity

CHMs, Chinese herbal medicines.

the follow-up period for non-CHMs users was the date
of the type 2 diabetes diagnosis; the index date for the
follow-up period for CHMs users was the first date of the
initiation of CHMs service. The end date of the follow-up
period for both groups was the earliest of the following:
(1) having a diagnosis of CRC; (2) withdrawing from the
insurance program or (3) the date of December 31, 2012.
Covariate assessment
Covariates comprised the baseline sociodemographic
characteristics and comorbidities. Sociodemographic
data included patient’s age, sex, income (for estimating
insurance payments) and urbanization level of the residential area. Monthly income was stratified into New
Taiwan Dollar (NTD) ≤17 880; NTD 17 881–NTD 43 900
and ≥NTD 43 901. Urbanization levels were divided into
urban (levels 1–2), suburban (levels 3–4) and rural (levels
5–7). Level 1 refers to the “most urbanized” communities and level 7 refers to the “least urbanized”.16 Baseline comorbidities included hypertension (ICD-9-
CM
401–405), stroke (ICD-9-
CM 430–438), heart disease
(ICD-9-CM 410–429), chronic kidney disease (ICD-9-CM
BMJ Open Diab Res Care 2020;8:e000732. doi:10.1136/bmjdrc-2019-000732

585), depression (ICD-9-CM 296.2, 296.3, 300.4 and 311)
and rheumatologic disorders (ICD-9-CM 725–729); all
were based on each individual’s medical records for the
1 year prior to initial cohort entry.
Statistical analysis
We conducted χ2 test and t-test analyses to examine the
differences in demographic characteristics and comorbidities between patients with type 2 diabetes with and
without CHMs treatment. The incidence rate of CRC was
calculated as the number of cases per 1000 person-years
(PYs). Multivariate Cox proportional hazards regression
analysis was then applied to compute the HR with 95%
CI of CRC risk in association with CHMs use. To test the
robustness of the relationship between CHMs use and
subsequent CRC risk, we divided the CHMs users into two
subgroups: those who used CHMs for 30–365 days and
those who used CHMs for more than 365 days. Analysis
stratified by age and sex using Cox proportional hazards
regression was also conducted to assess the HR of CRC
among those who did and did not receive CHMs. Assumptions of the proportional hazards model were verified by
using plots of log (-log (survival)) function) versus log
(time) and Schoenfeld residuals versus time. All analyses
were conducted using SAS V.9.3 software (SAS Institute,
Cary, North Carolina, USA), at a p<0.05 statistically significant level.
Results
The CHMs user and non-CHMs user cohorts provided,
each, data for 14 940 subjects. After the matching procedure with propensity score, no significant differences
were observed between the two groups on age, sex,
monthly income, residential area and comorbidities,
indicating that the two groups were comparable with
regard to these variables (table 1).
Among all eligible subjects, 610 first episodes of CRC
occurred, 375 in non-CHMs users and 235 in CHMs users,
during follow-up periods of 151 745.04 and 135,251.86
PYs, respectively. The incidence rate of CRC was signifiCHMs users
cantly lower in CHMs users than in non-
(1.73 vs 2.47, respectively, per 1000 PYs), with an adjusted
HR of 0.71 (95% CI 0.60 to 0.84) (table 2). Of note, those
who used CHMs for more than 365 days had a lower risk
of CRC (95% CI 0.28 to 0.61) vs non-users by 59%.
Table 3 presents the results from this analysis stratified
by age and gender. Collectively, a more significant beneficial effect of CHMs was observed among younger subjects,
irrespective of sex. Furthermore, the multivariable stratified analysis verified that the benefit of CHMs therapy
for treating CRC was more predominant in males than
in females, with an adjusted HR of 0.66 and 0.76, respectively (table 3). The 10 most commonly prescribed herbal
formulae for those with type 2 diabetes are summarized
in table 4. Among them, one was a single-herb product
while the remaining products were multiple-herb products. Cox proportional hazards regression analysis
3

BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2019-000732 on 12 March 2020. Downloaded from http://drc.bmj.com/ on May 20, 2020 at Portland State University
Library-Serials. Protected by copyright.

Table 1 Demographic data and comorbidity comparison of
the study subjects

Epidemiology/Health Services Research

Patient group

Event

PYs

Incidence

Crude HR
(95% CI)

Adjusted HR*
(95% CI)

CHMs non-users
CHMs users

375
235

151 745.04
135 251.86

2.47
1.73

1.00
0.70 (0.60 to 0.83)

1
0.71 (0.60 to 0.84)

 CHMs use for 31–365 days
 CHMs use >1 year

208
27

108 166.55
27 085.31

1.92
1.00

0.78 (0.66 to 0.93)
0.40 (0.27 to 0.60)

0.79 (0.67 to 0.94)
0.41 (0.28 to 0.61)

Incidence rate is per 1000 PYs.
*Model adjusted for age, gender, urbanization level, monthly income and comorbidity.
CHMs, Chinese herbal medicines; PYs, patient-years.

showed that the use of Huang-Qin, Shu-Jing-Huo-Xue-
Tang, Xue-Fu-Zhu-Yu-Tang, Ji-Sheng-Shen-Qi-Wan, Liu-
Wei-Di-Huang-Wan, Gan-Lu-Yin, Shao-Yao-Gan-Cao-Tang
and Ban-Xia-Xie-Xin-Tang was significantly associated
with lower risk of CRC (table 4).
Discussion
This is the first evidence-based cohort study addressing
the association between CHMs use and CRC risk in
patients with type 2 diabetes through a large nationwide claims-based data source. In this follow-up study
of 15 years (1998–2012), we found that patients with
type 2 diabetes who were receiving CHMs had a nearly
30% lower chance of CRC than those not using CHMs.
Furthermore, those receiving CHMs for more than 365
days were found to have a lower risk of CRC by nearly
60%. The dose-
response relationship may elucidate
the causality between CHMs use and the decrease in
the predisposition for developing CRC. No previous
studies have been conducted to determine the long-
tern impact of CHMs on CRC risk among patients with
type 2 diabetes, thus rendering a comparison of results
impossible. However, the findings obtained herein are
consistent with earlier research findings and add to the

growing body of knowledge on the beneficial effects of
CHMs for the patients with chronic diseases.6–8
The effect of CHMs was further analyzed with stratification by age and sex. Taken together, the use of CHMs
was found to have a greater effect on CRC risk in younger
patients irrespective of their sex, and th finding echod
these of previous studies.7 8 We speculated that younger
patients may have fewer coexisting medical conditions or
possess better medical knowledge and coping resources,
in addition to demonstrating more positive attitudes
toward medical impairments,17 thus enhancing the
preventive impact of CHMs on CRC risk.
An additional contribution of the present study is
the list of Chinese herbal products that were found
to be beneficial in reducing CRC risk. For example,
Huang-Qin is one of the most common CHMs used to
treat type 2 diabetes and it may help in lessening the
subsequent risk for CRC. Wogonin, the main ingredient
in Huang-Qin, was found to have antineoplastic and anti-
inflammatory effects in both in vitro and in vivo studies.
One study found that wogonin can induce activation of
AMP-
activated protein kinase (AMPK), to inhibit the
proliferation and induce apoptosis in cancer cells.18 Additionally, other researchers have proposed that wogonin

Table 3 Age-specific and sex-specific incidence and adjusted HR of colorectal cancer in relation to CHMs use in patients
with type 2 diabetes
CHMs non-users
Variables

Case

CHMs users

PYs

Incidence

Case

PYs

Incidence

Adjusted HR
Crude HR (95% CI) (95% CI)

Female
 ≤50 years

33

26 100.8

1.26

17

26 277.02

0.65

0.50 (0.28 to 0.90)

0.50 (0.27 to 0.89)*

 >50 years

154

58 674.38

2.62

107

48 944.48

2.19

0.84 (0.66 to 1.07)

0.84 (0.65 to 1.07)*

 All

187

84 775.18

2.21

124

75 221.5

1.65

0.76 (0.59 to 0.94)

0.76 (0.61 to 0.96)†

 ≤50 years

39

25 323.32

1.54

20

22 241.56

0.90

0.60 (0.35 to 0.98)

0.59 (0.34 to 0.97)*

 >50 years
 All

149
188

41 646.54
66 969.86

3.58
2.81

91
111

37 788.8
60 030.36

2.41
1.85

0.67 (0.52 to 0.87)
0.65 (0.52 to 0.83)

0.68 (0.52 to 0.88)*
0.66 (0.53 to 0.84)†

Male

Incidence rate is per 1000 PYs.
*Model adjusted for urbanization level, monthly income and comorbidity.
†Model adjusted for age, urbanization level, monthly income and comorbidity.
CHMs, Chinese herbal medicines; PYs, person-years.
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Table 2 Crude and adjusted HR of colorectal cancer for patients with type 2 diabetes with and without CHMs treatment
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Ingredients or generic name

Frequency of
prescriptions

Crude HR
(95% CI)

Adjusted HR *
(95% CI)

Scutellariae radix

15 796

0.67
(0.52 to 0.84)

0.68
(0.56 to 0.90)

 Shu-Jing-Huo-
Xue-Tang

Paeoniae radix, Angelicae radix, Atractylodis lanceae rhizome, Cnidii
18 503
rhizome, Persicae semen, Poria, Rehmanniae radix, Achyranthis
radix, Clematis radix, Gentianae scabrae radix, Notoptergii rhizome,
Saposhnikoviae radix, Sinomeni caulis et rhizome, Angelicae dahuricae radix,
Aurantii nobillis pericarpium, Glycyrrhizae radix, Zingiberis rhizoma

0.65
(0.54 to 0.78)

0.69
(0.56 to 0.81)

 Xue-Fu-Zhu-Yu-
Tang

Glycyrrhizae radix, Angelicae sinensis radix, Rehmanniae radix, Achyranthis
bidentatae radix, Persicae semen, Chuanxiong rhizoma, Platycodonis radix,
Carthami flos, Paeoniae radix rubra, Bupleuri radix, Aurantii fructus

11 664

0.56
(0.44 to 0.72)

0.60
(0.46 to 0.76)

 Ji-Sheng-Shen-
Qi-Wan

Rehmanniae radix preparata, Fructus corni, Cortex moutan, Rhizoma
dioscoreae, Poria and Rhizoma alismatis, Achyranthis bidentatae radix,
Aconiti lateralis praeparata radix, Cinnamomi cortex, Plantaginis semen

12 498

0.55
(0.42 to 0.72)

0.53
(0.40 to 0.69)

11 031

0.58
(0.49 to 0.67)

0.62
(0.53 to 0.72)

CHMs name
Single-herb products
 Huang-Qin
Multiherb products

 Liu-Wei-Di-Huang- Rehmanniae radix preparata, Fructus corni, Cortex moutan, Rhizoma
Wan
dioscoreae, Poria, Rhizoma alismatis
 Gan-Lu-Yin

Glycyrrhilza uralensis, Liriope spicata, Citrus sinensis, Rehmannia glutinose,
Artemisia capillaris, Eriobotrya japonica, Dendrobium nobile, Scutellaria
baicalensis and Asparagus cochinchinensis

9753

0.62
(0.47 to 0.81)

0.64
(0.49 to 0.84)

 Du-Huo-Ji-Sheng
Tang

Angelicae pubescentis radix, Taxilli herba, Eucommiae cortex, Cyathulae
radix, Asari radix, Gentianae macrophyllae radix, Poria, Cinnamomi cortex,
Saposhnikoviae radix, Chuanxiong rhizoma, Ginseng radix, Glycyrrhizae
radix, Angelicae sinensis radix, Paeoniae radix alba, Rehmanniae radix

9063

0.79
(0.64 to 0.97)

0.76
(0.61 to 1.01)

 Shao-Yao-Gan-
Cao-Tang

Paeoniae radix, Glycyrrhizae radix

8003

0.74
(0.60 to 0.91)

0.75
(0.57 to 0.89)

 Yu-Quan-Wan

Ophiopogonis radix, Ginseng radix, Poria, Astragali radix, Mume fructus,
Trichosanthis fructus, Glycyrrhizae radix, Puerariae lobatae radix

4932

0.88
(0.56 to 1.13)

0.92
(0.60 to 1.23)

 Ban-Xia-Xie-Xin-
Tang

Pinelliae rhizoma, Scutellariae radix, Zingiberis rhizoma, Ginseng radix,
Glycyrrhizae radix, Coptidis rhizoma, Jujubae fructus

4529

0.69
(0.52 to 0.91)

0.70
(0.54 to 0.97)

*Model adjusted for age, gender, urbanization level, monthly income and comorbidities.
CHMs, Chinese herbal medicines.

may suppress the production of interleukin (IL)-6 and
IL-1b by modulating the nuclear factor (NF)-kappa beta
and NF-E2-related factor 2 signaling pathways.19 IL-6 and
IL-1β are well known pleiotropic proinﬂammatory cytokines with profound effects on several diseases, especially
CRC onset.20 21
Findings of the present study revealed that the other
commonly-prescribed formulas targeting type 2 diabetes,
such as Xue-Fu-Zhu-Yu-Tang and Shu-Jing-Huo-Xue-
Tang, also significantly lowered CRC risk. Recently, both
animal experiments and human studies showed that
Xue-Fu-Zhu-Yu-Tang has anti-inflammatory and anti-
tumor effects, primarily via inhibiting the activation of
such intracellular signaling pathways as phosphoinositide
kinase-
protein kinase B-
mammalian target of rapa3-
22 23
mycin (PI3K-AKT-mTOR).
Blocking PI3K-AKT-mTOR
signaling may impact the expression levels of elements in
the tumor microenvironment, affecting cancer stem cell
expression and survival.24 In addition, the positive therapeutic effect of Shu-Jing-Huo-Xue-Tang on subsequent
risk of CRC may be inferred from its reported effect of
increasing blood circulation and enhancing antioxidant
enzymatic activity,25 in addition to its anti-inflammatory
BMJ Open Diab Res Care 2020;8:e000732. doi:10.1136/bmjdrc-2019-000732

activity.26 All of these processes have been implicated in
the development of colitis-associated neoplasia.27
Similar to a previous report,28 the current study showed
a preventive effect of Liu-Wei-Di-Huang-Wan on the risk
of CRC. This herbal product may induce the inactivation of the IGF pathway. IGF is well known to promote
malignant transformation, promoting cell proliferation
and dedifferentiation and inhibiting apoptosis, which in
turn predisposes the individual to developing cancer.29
Ji-Sheng-Shen-Qi-Wan, also known as Gosha-jinki-gan, is
widely used to treat patients with diabetic neuropathy.
This medication enhances nitric oxide (NO) production
and thereby increases blood circulation while inhibiting
blood coagulation.30 Recently, NO has been suggested
to modulate different cancer-related events, including
angiogenesis, apoptosis and metastasis,31 all possible
mechanisms for the positive effect observed here.
Gan-Lu-Yin was also found to decrease the risk of CRC.
In one study, relative to untreated controls, Gan-
Lu-
Yin-fed rats had markedly reduced cell proliferation and
migration, through the induced differentiation of WEHI-3
cells.32 This inhibition of angiogenesis may prevent subsequent tumor growth. Use of another common CHMs,
5
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0.79), respectively. Taken together, the results from the
reanalysis of the two sensitivity analyses lent support to
the earlier findings of this study. Fifth, although our study
revealed a substantial benefit resulting from the use of
CHMs among patients with type 2 diabetes, it must be
recognized that in our study patients were not randomly
categorized into users and nonusers of CHMs. Therefore,
potential biases may still remain, and in particular when
they stem from unmeasured or unknown confounders.
Caution, therefore, must be exercised when interpreting
these findings.
These limitations notwithstanding, this study also offer
several strengths. These include the immediate availability of data, the comprehensiveness of the database,
and the statistical power derived from the large sample.
In addition, a long observational period offers the opportunity to determine in detail the association between
CHMs usage and CRC risk among patients with type 2
diabetes, and the available findings may serve as a useful
reference for future studies focusing on additional clinical outcomes, such as colorectal neoplasm.

Conclusion
In summary, this large-
scale nationwide cohort study
demonstrates that the integration of CHMs, during treatment for type 2 diabetes, appears to lower the subsequent
risk of CRC by nearly 30%. We believe that these findings could serve as a reference for healthcare providers
in helping to establish more effective therapeutic interventions to improve the prognosis of patients with type
2 diabetes.
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Tang, was also related to a lower
risk of CRC. This compound may rescue the decreased
phosphorylation of glycogen synthase kinase 3 (GSK-3)
in patients with type 2 diabetes.33 Activation of GSK-3
would then downregulate the PI3K-AKT-mTOR signaling
pathway to inhibit colon cancer cell proliferation.34
Use of Ban-Xia-Xie-Xin-Tang was found to lessen the risk
of developing CRC in patients with type 2 diabetes. One
possible mechanism may involve the anti-inflammatory
properties of Ban-Xia-Xie-Xin-Tang,35 36 which is often
used to treat various digestive inflammations, like colitis,
esophagitis and gastritis.37 Chronic inflammation of the
bowel has been hypothesized as the most important
mechanism driving CRC onset.38
While our study is the first to investigate CHMs effect on
reducing CRC risk among patients with type 2 diabetes,
there are important limitations to consider. First, a
coding error may occur in the retrospective study design
due to factors related to the availability and accuracy
of the medical record. Therefore, we enrolled patients
with type 2 diabetes and CRC only after these patients
had at least three outpatient visits reporting consistent
diagnoses, or after the patients had at least one inpatient
admission. The CRC cases were further verified using the
catastrophic illness registry. It should also be noted that
the Taiwan NHI randomly audits hospital claims, interviews patients and reviews medical charts to verify the
accuracy of medical records. Second, the LHID does not
include detailed information on the risk factors associated with CRC, such as smoking, alcohol consumption,
level of obesity or dietary habits. Future research, considering these untested variables, is needed to better assess
whether the present findings are replicable across diverse
groups of individuals. Third, prescriptions for medications
issued before 1996 were not reflected in our data analysis.
This omission may have resulted in underestimation of
the cumulative frequency of prescriptions and therefore
may have weakened the apparent effects of the specified
herbal products. Although several commonly-prescribed
CHMs for patients with type 2 diabetes were identified
as influential in decreasing the risk of CRC, their therapeutic effect and safety concerns remain to be elucidated
in future pharmacological investigations. Fourth, we
conducted two sensitivity analysis to confirm the relationships of interest. First, we did not exclude those receiving
metformin with an average dose of more than 250 mg per
day (n=14 457). The reanalysis showed that the protective effect of CHMs was somewhat attenuated, but was still
statistically significant (adjusted HR=0.76; 95% CI 0.64 to
0.89). Second, all CRC cases were divided into two groups
based on the location of CRC, namely, the occurrence of
malignant neoplasm of colon and rectal cancer. Of the
610 CRC cases, 395 were of colon cancer and 215 cases
were attributed to rectal cancer. After adjusting for the
confounders, the reanalysis indicated that integrating
CHMs into the conventional therapy decreased the risk
of colon cancer and rectal cancer, with an adjusted HR
of 0.77 (95% CI 0.64 to 0.95) and 0.60 (95% CI 0.45 to
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